BofA raises Mineralys Therapeutics stock price target on NDA progress By Investing.com

BofA raised its price target on Mineralys to $51 (from $46) and kept a Buy after increasing lorundrostat's probability of success to 90% (from 80%) following FDA NDA acceptance and a PDUFA date of Dec 22, 2026, pointing to a potential H1 2027 launch. The stock trades at $26.99 after roughly a ~100% one-year gain; analyst consensus/InvestingPro indicate ~96% upside to fair value. Mineralys beat Q4 2025 EPS at -$0.40 vs consensus -$0.94, but management flagged higher G&A for the expected launch and there were mixed market reactions to recent trial data, creating near-term expense and data risks.

Analysis

The market is treating this as an asymmetric, option-like launch story: a high-probability regulatory path priced into expectations but with the bulk of value dependent on execution — launch sequencing, formulary placement, and rapid salesforce scale-up. Expect most dollar value to accrue after commercial throughput is validated (first full fiscal year of sales) rather than at acceptance, so the stock is sensitive to guidance revisions and early prescription trends.

Competitive dynamics favor a player that can demonstrate both differentiated efficacy/safety and a simple route to formulary access; if that combination occurs, incumbent generics producers and ARB/ACE inhibitor combo franchises face meaningful erosion in share among difficult-to-control hypertensives. Second-order beneficiaries include contract sales organizations, specialty pharmacies, and CMOs that can ramp capacity rapidly, while payers and PBMs will exert pricing pressure that can cap upside unless clear real-world benefit emerges.

Key tail risks: label compression, post-approval safety signals, and slower-than-modelled uptake due to narrow initial reimbursement or limited salesforce productivity. Time horizons break into near-term (weeks–months for regulatory/advisory catalysts and early uptake signals), medium-term (0–18 months for formulary negotiation and launch cadence), and long-term (3–5 years for peak market penetration), and any negative surprise at these checkpoints can erase a large portion of implied upside.

The consensus appears to underweight launch execution risk and payer pushback while over-weighting headline regulatory progress. That creates a clean risk-adjusted trade: buy optionality to the commercial upside while keeping downside limited to the sizable probability of a messy rollout or follow-on trial surprises.

Key Decisions for Investors

• Tactical long (MLYS): Initiate a small core long sized 0.10% NAV to capture idiosyncratic upside; add on clear early commercial signals (prescription trends, formularies) and trim hard on any evidence of payer restriction. Risk: regulatory or launch missteps; reward: multi-bag upside if uptake and reimbursement validate model.
• Replaceable optionality (MLYS options): Buy 18–30 month LEAP calls (Jan/Dec 2028 expiries) sized 0.02–0.05% NAV to retain upside convexity while limiting cash at risk to premium; consider 30/70 call spreads if implied vol is expensive to cap cost. Max loss = premium; asymmetric upside if launch executes.
• Hedge the binary (pair trade): Long MLYS equal-$ vs short XBI (or a small-cap biotech basket) sized to neutralize sector beta — isolates idiosyncratic commercialization outcome. Expect this to reduce portfolio volatility; unwind hedge on sustained positive commercial datapoints.
• Sell short-term calls to fund exposure: If already long equity, sell 3–6 month OTM calls to finance part of the LEAP premium and lower net cost; this conserves upside for the medium term but caps short-term gains and should be sized to preserve core exposure.